Equity Overview
Price & Market Data
Price: $2.44
Daily Change: +$0.03 / 1.23%
Daily Range: $2.37 - $2.47
Market Cap: $9,272,000
Daily Volume: 37,570
Performance Metrics
1 Week: 5.63%
1 Month: 7.49%
3 Months: -27.19%
6 Months: -69.49%
1 Year: -86.67%
YTD: 1.67%
Company Details
Employees: 19
Sector: Health technology
Industry: Medical specialties
Country:
Details
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.